Continuing pneumococcal vaccination in Kenya after transitioning from Gavi support is cost-effective

Research Brief, April 2019.



As their economies grow and they transition out of Gavi financial support, many low-income countries will need to consider the value of continuing their previously-subsidized vaccine programs at full cost. Using Kenya as a case example, this brief highlights results and policy implications of a study assessing the incremental cost-effectiveness of continuing PCV use between 2022 and 2032. The results can be used to inform Kenya’s decision whether to continue PCV use.